Boston Scientific Corporation
NYSEBSX short interest surges 38% in one week to 2.5% of float, driven by analyst downgrades and competitive headwinds in ablation markets.
Short interest % of float, cost to borrow, utilization, and put/call ratio for BSX are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Why this matters: Citigroup downgraded BSX to Neutral this week, slashing its target to $50 from $57. That move crystallised a bear case that short sellers began pricing in weeks ago — short interest has nearly doubled…
Boston Scientific enters the back half of August with an unusual combination: the CEO just made a nine-figure open-market purchase, short sellers are rebuilding positions at the fastest pace in months, and a wave of…
Snapshot as of 20 Sept 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BSX — free to start on ORTEX.
Sign up for free →Open BSX on ORTEX